

Use of Bisphosphonate or other Bone Remodeling agents in patients with stage 4 Breast Cancer with documented bone metastasis in (A follow up study for year 2016)
Abdulraheem Qasem MD

Introduction:

Bisphosphonates are category of medications that decrease pain from bone metastasis and may improve overall bone health. It is recommended by both NCCN guidelines and ASCO guidelines to be used in patients with bone metastases due to breast cancer. We conducted study last year to identify our use and utilization of this medicine in stage IV breast cancer with documented bone metastasis. The study showed use of bisphosphonate in 62.3% of patients with breast cancer and bone metastasis.

Study:

This is a follow up study for the previous study to assess use of bisphosphonate in the treatment of metastatic breast cancer with documented bone metastasis and to evaluate if the recommended interventions have resulted in increase use of bisphosphonate in this particular group of patients.

We did a retrospective chart review study for all patients diagnosed with stage IV breast cancer in 2016 to identify the rate of bisphosphonate use in patients with indication for the use of the medicine. Patients list obtained from tumor registry.

Results:

Eight patients were identified, one of them received her cancer care outside Truman medical center and her data were not available for review. Of the remaining seven patients, three patient bisphosphonate therapies were not indicated (two did not have significant bone metastasis at time of stage IV breast cancer diagnosis and the other one chooses hospice care). Of the remaining two patients, one received bisphosphonate and the other not. For the one who did not receive it, it looks like it was thought off by the treating physician but was not ordered.

Table -1

STUDY YEAR	2015	2016
Patient diagnosed with stage IV breast cancer	11	7
Patient received cancer care at TMC	8	6
Patient with indication for bisphosphonate	8	2
- Received Bisphosphonate	5 (62.5%)	1 (50%)
- Did not receive	3 (27.5%)	1 (50%)

bisphosphonate

Discussion:

We have a lower rate of use of bisphosphonate in patients with stage IV breast cancer in 2016 (50%) compared to (62.5%) in 2015. We need to interpret this numbers with caution given the very small number of patient whom bisphosphonate therapy was indicated. It is hard to conclude if we are doing better or worse that the last year.

Intervention:

1. Oncology Department to continue monitor rate of bisphosphonate use in patient with stage IV breast cancer and bone metastasis and conduct another study at the end of 2017 to reanalyze the data once adequate number of patients included.
2. Oncology department to continue to reach out to the community and the sponsors trying to obtain a fund for dental care to help the patient seen by dentist and undergo the needed treatment and intervention before starting the medicine.